Summit Therapeutics is trading at $13.35 (+4.26%) as the stock rebounds from recent biotech weakness and a broader market shift toward risk-on sentiment.
- The move is supported by improving sentiment in the technology and healthcare sectors alongside a stronger Nasdaq.
- No company-specific news or catalysts were identified to account for today's price action.
- The gain marks a recovery following recent downward pressure across the broader biotechnology industry.